Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

✍ Scribed by A. Garber; R. R. Henry; R. Ratner; P. Hale; C. T. Chang; B. Bode

• Book ID: 109046101
• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 971 KB
• Volume: 13
• Category: Article
• ISSN: 1462-8902
• DOI: 10.1111/j.1463-1326.2010.01356.x